The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a viral oncogene and it is essential for the transformation of resting B cells by the virus. The protein acts as a ligand-less membrane receptor and triggers numerous cellular signaling pathways. Cellular transformation frequently has been associated with genomic instability. To investigate whether EBV LMP1 induces chromosomal aberrations, micronucleus (MN) formation was examined in LMP1-expressing epithelial cells. The expression of wild-type LMP1 enhanced both spontaneous and bleomycin-induced MN formation. MN formation may be induced by inactivation of DNA repair and, therefore, we investigated the effect of LMP1 on DNA repair, using a host cell reactivation (HCR) assay. In the HCR assay, LMP1 reduced the capacity for DNA repair of both NPC-TW01 (p53-wild-type) and H1299 (p53-deficient) cells. As reduction of DNA repair by LMP1 occurs in p53-wild-type and p53-deficient cells, it seems that LMP1 can repress DNA repair in a p53-independent manner. Inactivation of DNA repair may render cells sensitive to DNA-damaging agents. In this study, H1299 cells harboring LMP1 were shown to be more sensitive to UV and bleomycin than those with a vector control. Using various deletion mutants of EBV LMP1 to determine the regions of LMP1 required to enhance MN formation, inhibit DNA repair and sensitize cells to DNA-damaging agents, we found that the region a. a. 189-222 (located within the CTAR1 domain) was responsible for sensitizing cells to UV and bleomycin, as well as for enhancing MN formation and repressing DNA repair. Based on these results, we suggest that disruption of DNA repair by LMP-1 results in an accumulation of unrepaired DNA and consequent genomic instability, which may contribute to the oncogenesis of LMP1 in human epithelial cells.
Introduction
Epstein-Barr virus (EBV) is a member of herpesviridae and the etiological agent of infectious mononucleosis (IM) (Henle et al., 1968) . It has also been associated with many human malignancies, including Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC) (Rickinson and Kieff, 2001) . NPC is a malignancy that develops from the epithelial cells of the postnasal cavity. It is one of the most important cancers in Southern Chinese males and used to be one of the 10 leading causes of cancer deaths in Taiwan. EBV was first associated with NPC through the serological detection of antibodies against the antigen expressed in a BL cell line (Old et al., 1966) . Further studies indicated that antibodies against EBV could be useful markers for the early detection of NPC patients (Henle and Henle, 1976; Zeng et al., 1982) . In our laboratory, we have examined the antibodies against EBV DNase, DNA polymerase, thymidine kinase, major DNA binding protein, BHRF1, viral capsid antigen (VCA) and ENBA1 in patients and controls, and found that all these antibodies could be useful markers for the detection of NPC (Chen et al., 1982 (Chen et al., , 1985 (Chen et al., , 1989 Liu et al., 1989 Liu et al., , 1997 Liu et al., , 1998 Hsu et al., 1992) . Among these was a prospective study carried out between 1983 and 1986 to examine the antibodies against EBV DNase and VCA in the inhabitants of NPC high-risk areas in Taiwan (Chen et al., 1989) . The relative risk of developing NPC over a 5-year period is 85.3 times higher for EBV antibody-positive than antibody-negative individuals and 32.8 times greater over 16 years of follow-up (Chien et al., 2001) . This result suggests strongly that EBV must play a certain etiological role in the carcinogenesis of NPC.
The activation of oncogenes, inactivation of tumor suppressor genes and interference with apoptosis have been implicated in the process of carcinogenesis by oncogenic viruses. To elucidate the mechanism of carcinogenesis in NPC, much effort has been expended in examining the activation of oncogenes and inactivation of tumor suppressor genes. Through years of studies, with only few exceptions, no apparent common feature was found to be associated with the development of NPC. However, cytogenetic studies have revealed many chromosomal abnormalities in NPC tissues (Cheng et al., , 1999 Gulley et al., 1998; Huang et al., 1989 Huang et al., , 1991 Lo et al., 1992 Lo et al., , 1995 Spruck et al., 1992; Sun et al., 1992 Sun et al., , 1995 Lung et al., 1998; Chang et al., 2002; Shao et al., 2001) . These results suggest that genome instability may be a common feature in the development of NPC.
Human T-cell leukemia virus 1 (HTLV-1) is the etiological agent of adult T-cell leukemia (ATL). Approximately 5% of HTLV-1 infected individuals develop ATL after an incubation period of several decades (Hinuma et al., 1981) . For NPC, most patients are infected by EBV early in their life and the incidence of disease peaks at the age of around 30-50 years. Thus, these two viruses seem to share some similarities in their biological characteristics in inducing their respective tumors. The carcinogenesis of ATL by HTLV-1 has been studied for many years. Cytogenetic studies on HTLV-1-transformed T lymphocytes revealed that most of the cells contained chromosomal abnormalities such as deletions and translocations (Chieco-Bianchi et al., 1988; Fujita et al., 1989; Maruyama et al., 1990; Kamada et al., 1992; Macera et al., 1996) . These results suggest that genome instability is also a common feature of ATL. Subsequent study revealed that HTLV-1 Tax induced micronucleus (MN) formation in COS cells, suggesting that Tax may function in the formation or accumulation of chromosomal damage (Majone et al., 1993) . It was found that Tax is also able to disrupt nucleotide excision repair (NER) (Kao and Marriott, 1999; Philpott and Buehring, 1999) . A hypothesis was proposed to explain the carcinogenesis of HTLV-1 in ATL, in that HTLV-1 may transform infected cells by inducing genomic instability and, most likely, by inhibiting cellular repair of spontaneous DNA damage (Philpott and Buehring, 1999) .
Taking the similarity between HTLV-1/ATL and EBV/NPC into consideration, we sought to address the following questions: does EBV contain gene(s) functionally equivalent to Tax in HTLV-1 and, if so, does that gene(s) function in suppressing the repair of damaged DNA? In this study, using MN formation and host cell reaction (HCR) assays, we demonstrate that the EBV latent membrane protein (LMP1) is able to enhance DNA-damage-induced MN formation and reduce the cellular capacity for DNA repair. These results provide, to our knowledge, a new mechanism through which EBV might contribute to the carcinogenesis of NPC through the enhancement of genomic instability.
Results

LMP1 enhances MN formation
Micronuclei are small nuclei arising from acentric chromatids or chromosome fragments induced by radiation (Thoday, 1951) . MN formation is related to chromosomal aberration and has been used widely to measure chromosome damage (Matsuoka et al., 1992; Stopper et al., 1997; Fenech, 2002) . To investigate whether EBV LMP1 can induce MN formation in human epithelial cells, we examined the micronuclei in RHEK-1 and LMP135 cells in the presence or absence of the DNA-damaging agent bleomycin. We calculated the frequency of MN formation and found that more micronuclei were observed in LMP135 cells than in RHEK cells, in the absence of bleomycin (3.9 vs 1.9%) (Figure 1a ). In the presence of bleomycin, MN formation was markedly enhanced (16.4 and 6.5% in LMP135 cells and RHEK-1 cells, respectively) ( Figure 1a) . The data indicate that the expression of LMP1 not only induces MN formation but also enhances DNA damage-induced MN formation. Comparing the levels of LMP1 expression in EBV-immortalized LCL and LMP135 cells, a high expression was found in LMP135 cells (Lu et al., 1996; Figure 1b) . To confirm this phenomenon further, LMP1 was expressed in RHEK-1 cells using a Tet-On expression system. Through Western blot analysis, LMP1 expression was found to be induced by doxycycline in a dose-dependent manner in the RHEK/tet-LMP1 cells (Figure 1d ). We then examined the effect of bleomycin on RHEK/tet-LMP1 cells and found that bleomycin could also induce MN formation in a dose-dependent manner (Figure 1c) . Furthermore, induction of LMP1 by doxycycline (1 mg/ ml) was found to result in a drastic increase in the number of micronuclei in the presence of bleomycin (Figure 1c ). The result is consistent with that in LMP135 cells (Figure 1a ). Although doxycycline induced MN formation in a dose-dependent manner in RHEK/tet-LMP1 cells, it did not affect MN formation in RHEK-1 cells (Figure 1d ). Thus, all the results support the hypothesis that LMP1 enhances MN formation in human epithelial cells.
Identification of LMP1 domains required for enhancement of MN formation
To determine the domain(s) of LMP1 required for enhancement of MN formation, we constructed various LMP1 mutants in the pIRESpuro2 vector, which makes it convenient to establish stable transfectants through puromycin selection. Recombinant plasmids were constructed containing wild type, mutant 350 (deleted CTAR2) and mutant D189-222 (deleted CTAR1) (see Materials and methods; Figure 2a ). LMP1 mutants in pIRESpuro2 vector were transfected into H1299/bcl2 cells and transfected cells were selected with puromycin. Puromycin-resistant cells were collected and expanded further. The levels of LMP1 expression in these stable transfectants are similar to those in EBV-immortalized LCL (Figure 2b) . We examined the numbers of micronuclei in these cell lines and found that mutant D189-222 was partially reduced in its ability to enhance MN formation, although mutant 350 was not (Figure 2c ). In the presence of bleomycin, mutant D189-222 had a decreased ability to enhance MN formation. These results indicate that the CTAR1 domain is essential for enhancement of DNA damageinduced micronuclei.
LMP1 represses DNA repair and its CTAR1 domain is required
As LMP1 was shown to enhance MN formation, we suspected that it might exert that effect by repressing of DNA repair. To address this possibility, we used an HCR assay to investigate the effect of EBV LMP1 on DNA repair. In this assay, plasmids expressing either an empty vector or LMP1, and either a UV-damaged or untreated luciferase reporter plasmid (pCMV-Luc), were cotransfected into various human epithelial cells, including NPC-TW01, H1299 and H1299/bcl2.
Compared with cells transfected with empty plasmids (pSG5), cells transfected with LMP1 could reduce the repair of the UV-damaged reporter plasmid to 0.53-0.77 (Po0.005, t-test) in three cell lines ( Figure 3a ). As LMP1 reduced DNA repair in both NPC-TW01 (wildtype p53) and H1299 (null p53) cell lines, it seemed that reduction of DNA repair by LMP1 can occur in a p53-independent manner. To confirm the effect of LMP1 on DNA repair, various amounts of LMP1-expressing plasmids were transfected into H1299/bcl2 cells. The data indicated that LMP1 repressed DNA repair in a dose-dependent manner (Figure 3b ). To identify the RHEK-1 and LMP135 cells were treated with bleomycin (500 mM) or untreated for 48 h, fixed with 100% methanol for 1 h, stained with DAPI (1 mg/ml) for 5 min, and the micronuclei in cells were examined using a fluorescence microscope. (b) The levels of LMP1 expressed in EBV-immortalized LCL, RHEK-1, LMP135 and RHEK/tet-LMP1 cells. Equal amounts (10 mg) of protein extracts from various cells or 2 mg from LMP135 cells were analysed using antibodies against LMP1 and b-actin. RHEK/tet-LMP1 cells (RHEK-1 cells stably harboring pRevTRE-LMP1) were incubated with 1 mg/ml of doxycycline for 24 h ( þ dox) or untreated. (c) MN formation in RHEK/tet-LMP1 cells. RHEK/tet-LMP1 cells were incubated with 1 mg/ml of doxycycline for 24 h, and then treated with various concentrations (50, 100, 250 nM) of bleomycin or mock treated for 48 h. (d) MN formation and the levels of LMP1 expressed in RHEK-1 and RHEK/tet-LMP1 cells. RHEK-1 and RHEK/tet-LMP1 cells were incubated with various concentrations of doxycycline for 24 h, and then treated with 100 nM of bleomycin or mock treated for 48 h. The inserted panel shows the levels of expressed LMP1 and b-actin by Western blotting analysis. For micronuclei assay, the data presented represent the means and standard deviations of three independent experiments. At least 1000 cells were counted for each experiment regions of LMP1 required for suppression of DNA repair, various LMP1 mutants were used in the HCR assay. Mutant 350 was able to reduce DNA repair to levels with a similar effect to wild-type LMP1; however, mutant D189-222 had lost the ability to repress DNA repair (Figure 3c ). These results indicated that a region including residues 189-222 (CTAR1 domain) is essential for the effect of LMP1 on DNA repair.
LMP1 sensitization of cells to DNA damage and the domain involved in this effect
Inactivation of DNA repair usually sensitizes cells to DNA-damaging agents. To investigate whether LMP1 made cells sensitive to UV and bleomycin, H1299/bcl2 cells harboring pIRESpuro2 (vector control), puro-LMP1-386 (wild type), puro-LMP1-350 or puro-LMP1-D189-222 were treated with UV (15 J/m 2 ) or bleomycin (0.25-8 mM) and cell viability was determined. After exposure to UV, H1299 cells with wild-type LMP1 and puroLMP1-350 were found to have a lower survival rate than those of vector control and mutant D189-222 (Figure 4a) . Similarly, cells with wild-type LMP1 and puro-LMP1-350 are also more sensitive to bleomycin than those with vector control and mutant D189-222 (Figure 4b ). These data indicate that LMP1 sensitized cells to DNA-damaging agents and, again, the CTAR1 domain (a. a. 189-222) is responsible for this effect. 
Discussion
EBV has been associated closely with many epithelial tumors, including NPC. However, the role of EBV in the carcinogenesis of epithelial cells has not been fully elucidated yet. In contrast to the situation in B lymphocytes, the transforming genes such as EBNA1, EBNA2 and LMP1 of EBV did not display the same biological effects on epithelial cells. We demonstrated that the LMP1 induced apoptosis instead of transformation in RHEK-1 cells (Lu et al., 1996) . We also found that EBNA-2 retarded the cell growth of HEp2, U2OS and NPC-TW01 cells (Lin et al., 2000) . Thus, a new mechanism is to be explored to elucidate the role of EBV in the carcinogenesis of epithelial tumors.
Chromosomal aberration is ubiquitous in all NPC tissues. Human cells are exposed to a variety of both endogeneous and exogenous genotoxic insults. Most of the damage is repaired through the DNA repair systems; however, the repair processes may not be perfect and, subsequently, those unrepaired lesions might give rise to cancer-prone mutations (Ames et al., 1995) . Therefore, both introduction of DNA damage and impairment of DNA repair lead to the accumulation of mutations and may contribute to the development of cancer.
The HTLV-1 Tax protein has been shown to induce and enhance chromosomal damage (Majone et al., 1993) and to disrupt NER (Kao and Marriott, 1999; Philpott and Buehring, 1999) . In the case of hepatitis B virus, the HBx protein was found to interact with a cellular DNA repair protein, XAP-1, which is a homologue of the human UV-damaged DNA-binding protein (UV-DDP) (Lee et al., 1995) . It was proposed that HBx expression might lead to the accumulation of mutations and ultimately to hepatocarcinogenesis (Capovilla et al., 1997) . In the case of human papillomavirus 16 (HPV 16), E6-expressing human colon carcinoma RKO cells were found to have a reduced capacity to repair UV-induced DNA lesions (Smith et al., 1995) . Furthermore, E6 and E7 of HPV 16 were demonstrated to induce chromosome instability in neonatal foreskin NHK cells (Duensing and Munger, 2002) . Thus, it does not seem uncommon for viruses to contribute to carcinogenesis through damaging DNA and repressing DNA repair.
In this study, EBV LMP1 was constitutively expressed in RHEK-1 cells (LMP135 cells). Then, both RHEK-1 cells and LMP135 cells were treated with the DNAdamaging agent, bleomycin. After mock treatment, more micronuclei were observed in LMP135 cells than in RHEK-1 cells (3.9 vs 1.9%) and MN formation was enhanced markedly in the presence of bleomycin (16.4 and 6.5% in LMP135 cells and RHEK-1 cells, respectively) (Figure 1a) . The results imply that LMP1 may interfere with genomic stability in human epithelial cells.
Micronuclei are considered indicative of chromosomal damage and are used widely in testing chemicals that may induce cytogenetic damage (Heddle, 1973; Parry and Parry, 1987; Sternes and Vig, 1989) . As the frequency of MN formation may be increased due to the deficiency of cellular DNA repair ability, it would be interesting to determine whether EBV LMP1 has any effect on the DNA repair in transfected human epithelial cells. A variety of assays have been developed to investigate the DNA repair activity of the cell. Among them, plasmid HCR has been developed for measuring NER in UV and chemical-induced DNA damage (Jacob and Wollman, 1953; Van der Eb and Cohen, 1967; Aaronson and Lytle, 1970; Lytle et al., 1972; Blanco and Devoret, 1973; Abrahams and Van der Eb, 1976; Lehmann and Oomen, 1985; Protic-Sabljic and Kraemer, 1985; Klocker et al., 1986; Athas et al., 1991; Smith et al., 1995; Kao and Marriott, 1999; Philpott and Buehring, 1999; Kao et al., 2000) . In this study, using a luciferase reporter plasmid (pCMV-Luc), we found that the EBV LMP1 is able to repress the repair of a damaged plasmid in NPC-TW01 (wild-type p53), and H1299 (null p53) cells (Figure 3a) . The results indicate that LMP1 can inhibit NER in human epithelial cells through p53-inpendent pathways. Furthermore, when various amounts of LMP1 were cotransfected with the reporter luciferase plasmid, a dose-dependent repression was revealed (Figure 3b ), supporting the hypothesis that the inhibition of HCR is due to the effect of LMP1.
Human cells defective in DNA repair systems such as xeroderma pigmentosum are cancer-prone and hypersensitive to UV irradiation (Cleaver and Kraemer, 1989) . Cells with defective NER also have been shown to be more susceptible to the lethal effects of UV irradiation (de Vries et al., 1995; Sands et al., 1995) . It is conceivable that cells containing a viral protein that represses the DNA repair will be more susceptible to UV irradiation and more prone to malignancy. The HBx protein has the ability to bind XAP-1, a human homologue of the monkey UV-damaged DNA-binding protein (UV-DDB) (Lee et al., 1995; Butel et al., 1996) . It was also found to be able to sensitize liver cells to UV irradiation (Capovilla et al., 1997) . In this study, H1299/ bcl2 cells harboring LMP1 were shown to be more sensitive to UV and bleomycin than those with the vector alone (Figure 4a, b) . These results support the notion that cells defective in DNA repair are more susceptible to DNA-damaging agents.
EBV LMP1 is a 386-amino-acid membrane protein composed of a short cytoplasmic N-terminus, six transmembrane domains and a cytoplasmic C-terminus containing CTAR1 (a.a. 194-232) and CTAR2 (a.a. 351-386) domains (Huen et al., 1995) . Various mutants were used to determine as to which domain(s) may be involved in the induction of MN formation, HCR inhibition and enhancement of the DNA damageinduced lethal effect. In the MN formation assay, mutant D189-222, from which the CTAR1 domain was deleted, was partially reduced in its ability to enhance MN formation in H1299/bcl2 cells (Figure 2c ). In the presence of bleomycin, the reduction was much more prominent (Figure 2c ). However, mutant 350 did not show significant reduction in its ability to enhance MN formation (Figure 2c ). This result suggests that the CTAR1 domain may be responsible for the induction of chromosome aberration. Similarly, the mutant D189-222 was found to lose the ability to repress DNA repair in H1299/bcl2 cells. In contrast, mutant 350 retained the ability to repress HCR to a similar extent to that of the wild-type LMP1 (Figure 3c ). The result indicates that CTAR1 may be responsible for the repression of NER in the H1299/bcl2 cells. Finally, the LMP1 domain that contributes to the enhancement of UV and bleomycin sensitivity was investigated in H1299/bcl2 cells harboring vector control, wild-type LMP1, mutant 350 and mutant D189-222. The results show that H1299/bcl2 cells with wild-type LMP1 and mutant 350 have lower survival than those harboring vector control and mutant D189-222 (Figure 4) . The results support the finding that CTAR1 domain is responsible for repressing DNA repair and rendering the cells sensitive to DNAdamaging agents. All these results corroborate the notion that the LMP1 plays a role in the induction of genomic instability, at least partially through the repression of DNA repair in human epithelial cells. Furthermore, these effects exerted by LMP1 may be contributed by the CTAR1 domain of LMP1. The mechanism of CTAR1 involved in the induction of genomic instability and repressing DNA repair is currently under investigation in our laboratory.
Genomic instability appears to be a hallmark of NPC. Both genetic and environmental factors have been proposed to account for the development of NPC (Hildesheim and Levine, 1993) . Among the genetic factors, recently, we have found that genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1 are associated with the risk of developing NPC (Cho et al., 2003) . Among the environmental factors, EBV infection was associated closely with the development of NPC (Hildesheim and Levine, 1993) ; however, the mechanism that EBV may contribute to the carcinogenesis of NPC is not fully elucidated yet. Recently, it was found that EBV latent infection may enhance the genetic instability of human B cells and it was suggested that it could contribute to tumor progression (Gualandi et al., 2001) . In our results, we show here that EBV LMP1 may contribute to the genomic instability of human epithelial cells and may play a role in the initiation step by repressing NER of both exogenous and endogenous DNA damage. Our hypothesis is that EBV infection may occur many times during a human life and the accumulation of a variety of mutations through mechanisms such as the repression of DNA repair would lead ultimately to the development of tumor cells. If the tumor cells can evade immune surveillance, after clonal expansion, NPC may develop. Therefore, we conclude that, in addition to many other mechanisms that LMP1 may contribute to the carcinogenesis of NPC, LMP1 may induce genomic instability, possibly through inhibition of DNA repair, and contribute to the development of NPC.
Materials and methods
Cell culture
NPC-TW01 cells, a human NPC cell line (Lin et al., 1990) , H1299 cells, a human large cell lung carcinoma cell line with a deletion of the p53 gene (Mitsudomi et al., 1992) , and RHEK-1 cells, a nonmalignant cell line established from normal human foreskin keratinocytes infected with a hybrid virus, adenovirus-12-simian virus-40 (Rhim et al., 1985) , were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. LMP135 cells, derived from RHEK-1 cells, constitutively express EBV LMP1 (Lu et al., 1996) . To establish additional cell lines with the expression of LMP1 or its mutants, transfected cells were incubated in a medium containing 1 mg/ml puromycin. Puromycin-resistant clones emerged 2-3 weeks later. LMP1 expression in these drug-resistant cells was verified by Western blotting. H1299/bcl2 cells were established by transfecting pCDj-SV2-bcl-2-neo plasmid (a gift from Y Tsujimoto, Oska University Graduate School of Medicine, Osaka, Japan) (Tsujimoto, 1989) into H1299 cells and selection with G418 (800 mg/ml). The expression of bcl2 in H1299/bcl2 was verified by Western blotting. EBV-immortalized lymphoblastoid cell line (LCL) derived from primary human B cells infected with B95.8 strain EBV was maintained in RPMI-1640 supplemented with 10% fetal calf serum.
DNA constructs
The BglII-HindIII fragment of pRc/CMV (Invitrogen), which contains the CMV promoter, was inserted into the BglII/Hind III sites of the pGL3-Basic vector (Promega) to generate the reporter plasmid pCMV-Luc. Plasmid pSG5, pSG5-LMP1 and LMP1 deletion mutants D189-222 and 350 were described previously (Huen et al., 1995; Floettmann et al., 1998) . Mutants D189-222 and 350 were deleted at amino acids 189-222 and 350-386, respectively. Puro-LMP1-386 and puro-LMP1-350 were generated by insertion of fragments LMP1-386 and LMP1-350 into the EcoRI/BamHI site of pIRESpuro2 (Clontech). Fragments LMP1-386 and LMP1-350 were amplified by PCR using a forward primer LMP1L with an artificial EcoRI site (5 0 -CTGAATTCGATGGAACAC GACCTTG-3 0 ), reverse primers with artificial BamHI sites (LMP1R, 5 0 -CGGGATCCTTAGTCATAGTAGCTTAG-3 0 for LMP1-386 and LMP1-350, 5 0 -CGGGATCCTTAATCAT GACTATGACC-3 0 for LMP1-350) and pSG5-LMP1 as the template. The puro-LMP1-350 generated a stop codon at position 350 of the amino-acid sequence of LMP1. Plasmid puroLMP1-D189-222 was constructed by insertion of an EcoRI/EcoRI fragment of pSG5-LMP1-D189-222 into the EcoRI site of pIRESpuro2. Plasmid pRevTRE-LMP1 was generated by insertion of an EcoRI/EcoRI fragment of pSG5-LMP1 (filled in using the Klenow enzyme) into the BamHI site (filled in using the Klenow enzyme) of pRev-TRE (Clontech).
MN formation
Cells were seeded onto coverslips for 24 h and then treated with bleomycin (indicated concentrations) or mock treated for 48 h. Cells were fixed with 100% methanol for 1 h at least and stained with 5,6-diamino-2-phenyl indole (DAPI, 1 mg/ml in methanol) for 5 min. Micronuclei in cells were examined using a fluorescence microscope. At least 1000 cells were counted for each experiment.
RevTet-On expression system for EBV LMP1
All procedures for the RevTet-On expression system were carried out as per the manufacturer's instructions (Clontech). First, the pRevTet-On vector was transfected into a packaging cell line RetroPack PT67. The resulting virus-containing supernatants were used to infect RHEK-1 cells to generate RHEK-ON cells. The cells were obtained through selection of G418 (1.2 mg/ml) and screening by transient transfection with pTRELuc as per the manufacturer's instructions. Secondly, the pRevTRE-LMP1 was transfected into a packaging cell line, RetroPack PT67, and the resulting viruses were used to infect RHEK-ON cells. Infected RHEK-ON cells were selected with hygromycin (400 mg/ml) and drug-resistant cells were treated with 1 mg/ml of doxycycline for 24 h to induce LMP1 expression, verified by Western blotting. The resulting cells (denoted RHEK/Tet-LMP1) were maintained for further analysis.
Western blotting analysis of LMP1 expression
The cellular extracts were separated by SDS-PAGE and transferred onto a Hybond-C super membrane (Amersham Biosciences Ltd). The blot was incubated with blocking buffer (10 mM Tris-HCl, pH 8.0, 0.9% NaCl and 4% skim milk) for 1 h and reacted with anti-LMP1 antibody, CS1-4 (Dako), diluted 1 : 200 for 1 h at room temperature. After washing three times with washing buffer (10 mM Tris-HCl, pH 7.4, 0.9% NaCl, 0.2% Tween-20), the blot was incubated with horseradish peroxidase-labelled goat anti-mouse IgG (Amersham Biosciences Ltd) diluted 1 : 2500 with blocking buffer for 1 h at room temperature. After incubation, the blot was washed three times in washing buffer and once with water, and then developed with a freshly prepared substrate (ECL Western blotting, Amersham Biosciences Ltd). The luminescence was detected by a short exposure to an X-ray film.
HCR assay
The HCR assay was as described by Tran et al. (2002) , using a luciferase gene as the reporter. Purified luciferase reporter plasmid DNA (pCMV-Luc), either damaged with 1000 J/m 2 of UV light or mock treated, an undamaged GFP reporter (pEGFP-C1) as internal control and effector plasmids (LMP1 and LMP1 mutants) were cotransfected into cells with Lipofectamine 2000 (Invitrogen), carried out as per the manufacturer's instructions. At 24 h post-transfection, cells were lysed in 150 ml lysis solution (0.1 M HEPES, pH7.8, 1% Triton X-100, 1 mM CaCl 2 and 1 mM MgCl 2 ) and assayed for GFP intensity and luciferase activity using 100 ml aliquots of the lysates. GFP intensity was measured first with FluroCount (Packard), and then 100 ml of luciferase substrate, LucLitet (Packard), was added to the lysates for luciferase activity measurement using a luminescence counter (Packard). The luciferase activity of each sample was normalized to the GFP intensity. To determine the ability to repair DNA, two parameters, repair conversion and fold of HCR were calculated as follows: repair conversion was calculated by dividing the normalized luciferase activity from cells transfected with UV-irradiated pCMV-Luc by that of nonirradiated pCMV-Luc transfectants. The fold of HCR was calculated by dividing the repair conversion of effector transfectants by that of vector tranfectants. Data from at least three independent experiments were averaged to calculate the mean and the standard deviation.
Analysis of cell survival
H1299/bcl2 cells harboring pIRESpuro2 (vector control), puro-LMP1-386, puro-LMP1-350 or puro-LMP1-D189-222 were seeded in 100-mm culture dishes (1000 cells per dish) and exposed to UV light (15 J/m 2 ) or mock treated. After 10 days of incubation, the cells were stained with 0.05% p-iodonitrotetrazolium violet dye and then colonies larger than 2 mm were counted. The cell survival rate was calculated by dividing the number of colonies after UV treatment by those of the mock-treated control. Cell survival after bleomycin treatment was determined by WST-1 assay performed as described in the manufacturer's instructions (Roche). Cells were seeded in 96-well plates at 1.5 Â 10 3 /well in the presence of bleomycin (0-8 mM). After incubation for 3 days, reagent WST-1 was added to the medium and incubated for 1 h, and then the absorbance (A 450 -A 650 ) of the samples was determined using a microtiter plate reader. The cell survival rate was calculated by dividing the values of absorbance (A 450 -A 650 ) of cells in the presence of bleomycin by those in the absence of bleomycin.
